William Blair
http://www.williamblair.comWilliam Blair & Company, L.L.C. is a Chicago-based investment firm offering investment banking, asset management, equity research, institutional and private brokerage, and private capital to individual, institutional, and issuing clients. Since 1935, it has been committed to helping clients achieve their financial objectives.
View Older Stories View More Recent Stories
-
Form NPORT-P WILLIAM BLAIR FUNDS For: Jun 30
-
Form NPORT-P WILLIAM BLAIR FUNDS For: Jun 30
-
Form NPORT-P WILLIAM BLAIR FUNDS For: Jun 30
-
Form NPORT-P WILLIAM BLAIR FUNDS For: Jun 30
-
Form NPORT-P WILLIAM BLAIR FUNDS For: Jun 30
-
Form NPORT-P WILLIAM BLAIR FUNDS For: Jun 30
-
Form NPORT-P WILLIAM BLAIR FUNDS For: Jun 30
-
Form NPORT-P WILLIAM BLAIR FUNDS For: Jun 30
-
Harvest Partners Completes Sale of Service Express to Warburg Pincus
-
Transact Campus Inc., a Reverence Capital Partners Portfolio Company, Announces Sale to Roper Technologies, Inc. (NASDAQ: ROP) for $1.6bn
-
Ethiopia bondholders disappointed by proposed bond haircut
-
William Blair Starts Korro Bio Inc. (KRRO) at Outperform
-
William Blair Reiterates Market Perform Rating on Starbucks (SBUX)
-
William Blair Reiterates Outperform Rating on On Holding AG (ONON)
-
William Blair Reiterates Outperform Rating on Chipotle Mexican Grill (CMG)
-
EQT Private Equity to acquire majority stake in AMCS, the leading provider of Performance Sustainability
-
Haveli Investments and Bregal Milestone Lead Majority Recapitalization of M-Files Corporation
-
William Blair Comments on Datadog (DDOG) Post Mgmt Meeting
-
William Blair Reiterates Outperform Rating on monday.com Ltd. (MNDY)
-
William Blair Downgrades Neuronetics (STIM) to Market Perform
-
Moody's and S&P doubt Boeing will hit year-end production targets
-
William Blair Downgrades Revance Therapeutic (RVNC) to Market Perform
-
Form 13F-HR BLAIR WILLIAM & CO/IL For: Jun 30
-
Tenax Therapeutics (TENX) Announces Closing of $100 Million Private Placement and Plans to Accelerate the Oral Levosimendan Phase 3 Program
-
Tenax Therapeutics Announces Closing of $100 Million Private Placement and Plans to Accelerate the Oral Levosimendan Phase 3 Program
-
William Blair Downgrades Brilliant Earth Group Inc (BRLT) to Market Perform 'on Increasingly Murky Recovery Outlook'
-
Zevra Therapeutics (ZVRA) Prices 9.23M Share Offering at $6.50/sh
-
Palomar Holdings Inc. (PLMR) Prices 1.2M Share Offering at $88/sh
-
William Blair Upgrades Blend Labs (BLND) to Outperform
-
Zevra Therapeutics Announces Pricing of Underwritten Offering of Common Stock
-
Palomar Holdings, Inc. Announces Pricing of Public Offering of Common Stock
-
Form 13F-HR WILLIAM BLAIR INVESTMENT For: Jun 30
-
Zevra Therapeutics (ZVRA) Announces Proposed Share Offering
-
Zevra Therapeutics Announces Proposed Public Offering of Common Stock
-
Tenax Therapeutics (TENX) Announces $100M Private Placement
-
Tenax Therapeutics Announces Oversubscribed $100 Million Private Placement
-
William Blair Reiterates Underperform Rating on Palantir Technologies Inc. (PLTR)
-
William Blair Upgrades Frontdoor Inc. (FTDR) to Outperform
-
William Blair Reiterates Outperform Rating on Amazon.com (AMZN)
-
DuraServ Partners With Leonard Green & Partners
-
Johnson Controls and Truelink Capital Management Close Transaction to Establish Air Distribution Technologies as Independent Business
-
MSCI (MSCI) Appoints Michelle Seitz to its Board
-
Michelle Seitz Appointed to MSCI Inc. Board of Directors
-
William Blair Upgrades Pegasystems (PEGA) to Outperform
-
PayPal's turnaround plan faces challenges from competition, analysts say
-
William Blair Starts Applied Therapeutics (APLT) at Outperform
-
Crawford & Company® to Participate in the William Blair Insurance, Banking & Wealth Conference
-
Vālenz® Health Completes Acquisition of Healthcare Bluebook™ to Create Innovative, Data-Driven Platform for Member Engagement, Value Navigation and Payment Integrity
-
Excellere Partners is Pleased to Announce That It Has Hired Two New Associates
-
Atlanticus Closes $60 Million Principal Amount of 9.25% Senior Notes Due 2029 in Add-On Offering

